Clinical Trial Update: Study to Evaluate Safety and Immunogenicity of the GSK Bio CMV Vaccine in CMV-seronegative Healthy Male Adult Subjects [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety and immunogenicity of GlaxoSmithKline's cytomegalovirus vaccine in CMV-seronegative healthy male adults; the trial status is com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Drugs mentioned

• GSK Bio CMV Vaccine (cytomegalovirus vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Cytomegalovirus | Phase 1 | Status: COMPLETED